Company
iQure
Astrocyte-targeted therapeutics to restore glutamate balance in CNS disorders
Also known as iQure Pharma, iQure Pharma Inc
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- iQure Pharma Inc
Claim, correct or request removal
Record updated 28 September 2026
About
iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics designed to restore glutamate balance in CNS disorders.
Funding snapshot
- Total raised
- $5.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Grant2026-06-18
Funding rounds
- Round, 2026
- $650K2026-05-27, SEC form D sold, 1 investor
- Round, 2025
- $2.8M2025-09-09, SEC form D sold, 14 investors
- Round, 2025
- $4M2025-01-07, Company stated
- Round, 2024
- $1.4M2024-12-20, SEC form D sold, 2 investors
- Round, 2024
- $220K2024-04-05, SEC form D sold, 7 investors
- Round, 2023
- $1.5M2023-10-04, SEC form D sold, 13 investors
Products
- Other
- iQ-007
Loading relationship preview